Abstract
Tofogliflozin (Apleway(®), Deberza(®) [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.K. and Kowa. Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglcaemic agents. This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.
MeSH terms
-
Animals
-
Benzhydryl Compounds / administration & dosage
-
Benzhydryl Compounds / pharmacology
-
Benzhydryl Compounds / therapeutic use*
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / physiopathology
-
Drug Approval
-
Drug Therapy, Combination
-
Glucosides / administration & dosage
-
Glucosides / pharmacology
-
Glucosides / therapeutic use*
-
Humans
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Japan
-
Sodium-Glucose Transporter 2 Inhibitors
Substances
-
Benzhydryl Compounds
-
Glucosides
-
Hypoglycemic Agents
-
Sodium-Glucose Transporter 2 Inhibitors
-
6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol